GenSight Undeterred By Gene Therapy’s Placebo Puzzle

 
• By Andrew McConaghie

Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain

Eye test
GenSight preparing to file in 2020 • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies